Study On The Screening And Activity Of Anti-Diabetic Peptides

Diabetes Mellitus is a common chronic metabolic disease, characterized by high blood glucose. In modern life, diabetes has a serious impact on people’s life. 2 million will do. With the increasing number of cases and the development of the medical science, the drugs for the treatment of diabetes have also made new progress.Diabetes is divided into: type 1 diabetes; type 2 diabetes, wherein type 2 accompanied by metabolic disorders caused by the lack of insulin. The number of βcells decreases, the secretion of insulin is relatively insufficient, so the blood glucose can not be maintained at the normal level. Therefore, the control of disease development mainly depends on the numbers of βcells’ increasing to maintain normal insulin secretion. With the rapid development of the medical science, the researchers focused on the target of the treatment of diabetes, the development of the related drugs has become the current hot spots.Exendin-4 is a 39 a peptide acid peptide secreted by Gila monster salivary glands in the southwest of American, similar to glucagon like peptide-1(GLP-1) which can reduce the blood glucose. Compared to the GLP-1, there is more than 53% homology of the a peptide acid residue in Exendin-4 with similar physiological function to GLP-1. Exendin-4 can promote β cells proliferation, increase the number of βcells and restore the function of β cells. Based on the hypoglycemic effect of Exendin-4, which have high homology and active short peptide simulation peptide and 17 peptide(17PA and 17 PB) with Exendin-4 and the better activity than Exendin-4 has been synthesized by using peptide library screening technology. In the study for 17 peptide, they were detected by a series of cell level and animal level. The study is useful to develop a new type of hypoglycemic agents to accumulate the data, it also provides important structural information for the development of oral class peptide drugs.